SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-96870"
 

Search: onr:"swepub:oai:DiVA.org:uu-96870" > Duration and degree...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET

Syvänen, Stina (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Blomquist, Gunnar (author)
Sprycha, Margareta (author)
show more...
Höglund, A. Urban (author)
Roman, Magnus (author)
Eriksson, Olof (author)
Hammarlund-Udenaes, Margareta (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Långström, Bengt (author)
Uppsala universitet,Institutionen för biokemi och organisk kemi
Bergström, Mats (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
show less...
 (creator_code:org_t)
Elsevier BV, 2006
2006
English.
In: NeuroImage. - : Elsevier BV. - 1053-8119 .- 1095-9572. ; 32:3, s. 1134-1141
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Active efflux transporters in the blood-brain barrier lower the brain concentrations of many drug molecules and endogenous substances and thus affect their central action. The objective of this investigation was to study the dynamics of the entire inhibition process of the efflux transporter P-glycoprotein (P-gp), using positron emission tomography (PET). The P-gp marker [C-11]verapamil was administered to anesthetized rats as an i.v. bolus dose followed by graded infusions via a computerized pump system to obtain a steady-state concentration of [C-11]verapamil in brain. The P-gp modulator cyclosporin A (CsA) (3, 10 and 25 mg/kg) was administered as a short bolus injection 30 min after the start of the [C-11]verapamil infusion. The CsA pharmacokinetics was studied in whole blood in a parallel group of rats. The CsA blood concentrations were used as input to model P-gp inhibition. The inhibition of P-gp was observed as a rapid increase in brain concentrations of [C-11]verapamil, with a maximum after 5, 7.5 and 17.5 min for the respective doses. The respective increases in maximal [C-11]verapamil concentrations were 1.5, 2.5 and 4 times the baseline concentration. A model in which CsA inhibited P-gp by decreasing the transport of [C-11]verapamil out from the brain resulted in the best fit. Our data suggest that it is not the CsA concentration in blood, but rather the CsA concentration in an effect compartment, probably the endothelial cells of the blood-brain barrier that is responsible for the inhibition of P-gp.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Keyword

PET
["C]verapamil
p-glycoprotein
cyclosporin
pharmacokinetics
modeling
blood-brain barrier
active efflux
PHARMACY
FARMACI

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • NeuroImage (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view